Date: 2012-10-25
Type of information: Licensing agreement
Compound:
Company: Amgen (USA - CA) Kleiner Perkins Caufield & Byers (USA - CA) Atara Biotherapeutics (USA - CA)
Therapeutic area: Cancer - Oncology - Kidney diseases - Renal diseases
Type agreement: licensing creation of a new company
Action mechanism:
Disease:
Details: * On October 25, 2012, Amgen and Kleiner Perkins Caufield & Byers (KPCB) announced the formation of Atara Biotherapeutics, a new drug development company with a focus on innovative therapies for patients with chronic diseases in therapeutic areas including nephrology and oncology. Atara Biotherapeutics will have licenses to six Amgen assets, which are in various stages of development, ranging from preclinical to Phase 1. Atara Biotherapeutics will be financed initially by KPCB, and Isaac Ciechanover, M.D., a former partner at KPCB, will serve as the president and chief executive officer. Amgen will have a minority equity interest in Atara Biotherapeutics.
Financial terms: Financial terms of the transaction are not being disclosed.
Latest news:
